The findings highlight the dynamic role of gigaxonin in enhancing antiviral innate immune responses by targeting both TREX1 and cGAS, suggesting that targeting gigaxonin may constitute a novel therapeutic approach for combating infectious diseases. Here, TREX1 is linked to infectious disease.